PubRank

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Clinical Trial ID NCT01144338

PubWeight™ 41.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01144338

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2013 2.66
2 Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig 2013 1.55
3 The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol 2012 1.32
4 Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 2014 1.27
5 Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011 1.21
6 Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 2012 1.20
7 The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther 2010 1.12
8 Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes Metab Syndr Obes 2012 1.06
9 Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2014 1.05
10 Evolution of exenatide as a diabetes therapeutic. Curr Diabetes Rev 2013 1.00
11 SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 2016 0.98
12 Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. Cardiovasc Diabetol 2015 0.97
13 Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 2015 0.93
14 Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. Am Heart J 2015 0.93
15 Do GLP-1-based therapies increase cancer risk? Diabetes Care 2013 0.92
16 Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes. J Card Fail 2014 0.90
17 Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. Diabetes Metab Syndr Obes 2015 0.88
18 Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus. J Diabetes Investig 2015 0.87
19 Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. Vasc Health Risk Manag 2012 0.86
20 Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications 2014 0.86
21 Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach. World J Diabetes 2015 0.85
22 Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. Cardiovasc Diabetol 2013 0.84
23 Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovasc Diabetol 2015 0.84
24 How do we continue treatment in patients with type 2 diabetes when therapeutic goals are not reached with oral antidiabetes agents and lifestyle? Incretin versus insulin treatment. Diabetes Care 2013 0.84
25 Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation 2016 0.84
26 The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol 2013 0.83
27 Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents. Nephrol Dial Transplant 2015 0.82
28 Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab 2015 0.81
29 Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of stroke. J Cereb Blood Flow Metab 2015 0.81
30 Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol 2014 0.80
31 Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol. BMJ Open 2014 0.79
32 Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial. Diabetes Ther 2016 0.79
33 Current perspectives on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol 2016 0.79
34 A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes. Diabetes Ther 2012 0.78
35 Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. Vasc Health Risk Manag 2012 0.78
36 Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2017 0.77
37 Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies. Ther Adv Drug Saf 2012 0.76
38 Emerging utility of once-weekly exenatide in patients with type 2 diabetes. Diabetes Metab Syndr Obes 2015 0.76
39 Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists. Diabetes Metab Res Rev 2016 0.75
40 Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial. Herz 2016 0.75
41 Cardiovascular effects of anti-diabetes drugs. Expert Opin Drug Saf 2016 0.75
42 Diabetes Drugs and Cardiovascular Safety. Endocrinol Metab (Seoul) 2016 0.75
43 Blood pressure and cardiovascular effects of new and emerging antidiabetic agents. Curr Hypertens Rep 2014 0.75
44 Linagliptin as add-on therapy to insulin for patients with type 2 diabetes. Vasc Health Risk Manag 2013 0.75
45 Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications. Clin Pharmacol Ther 2015 0.75
46 Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements. Diabetes Metab Syndr Obes 2015 0.75
Next 100